Science
Our strategy is targeting the critical mechanisms shared by CNS diseases to develop therapies with broad utility.
Our Strategy
Currently, there is no "restorative" therapy that slows down disability progression or repairs function in multiple sclerosis (MS). For Alzheimer's disease (AD) and Amyotrophic lateral sclerosis (ALS), approved therapies moderately slow progression in early disease only. Our strategy is targeting the critical mechanisms shared by these CNS diseases to develop therapies with broad utilities.
Critical Mechanisms
Remyelination
Repair/protect ‘data cables’
When the myelin sheath is damaged, nerve impulses slow down or even stop, causing neurological problems. We devise strategies to promote the formation of the myelin sheath after damage to protect the axons and restore function.
Anti-neuroinflammation
Ameliorate brain environment
Neuroinflammation is a key pathological driver in many neurological diseases. We devise strategies to modulate the activities of two key immune cell types: microglia and CNS-infiltrating T cells, to alleviate neuroinflammation.
Myro Pipeline
